A patient with metastatic cancer does not experience oncology as a field of "breakthroughs." They experience it as a waiting room, a form, an insurance call that goes unanswered. And yet the science underneath them has never moved faster.
Here is the paradox in numbers.
- The science is outrunning the system
Registered cancer clinical trials increased at an annual rate of 7.3% between 2005 and 2021, according to WHO and IARC's first Global Status Report on Cancer. Overall five year relative survival in the US has climbed to 70%, and survival for metastatic disease has doubled since the mid 1990s, from 17% to 35%, per the American Cancer Society's 2026 Cancer Statistics report. For some of the hardest cancers, the gains are staggering: five year survival in myeloma rose from 32% to 62%, and in metastatic melanoma from 16% to 35%.
- Yet access has not kept pace with discovery
The same WHO report is blunt about why: scientific progress alone does not save lives if it never reaches the patient. Lack of access to essential cancer medicines remains one of the report's central concerns, especially outside high income countries. Even within the US, only about 18% of eligible people receive recommended lung cancer screening, and that rate drops below 13% for people under 60, according to the Cancer Research Institute's 2026 analysis, despite screening cutting mortality by up to 24% in high risk groups.
- The gap is structural, not just financial
It shows up in who gets diagnosed early enough for treatment to work. Localized lung cancer carries a 65% five year survival rate, distant stage disease sits at 10%. Only 28% of lung cancers and just 17% of pancreatic cancers are caught early. It shows up in who is represented in the trials that generate this progress in the first place, with later stage diagnoses and lower survival still disproportionately affecting Black patients, driven in part by unequal trial access, per the ACS report above. And it shows up after standard therapy fails, when a patient's best option may be a clinical trial they were never told about, or an early access pathway their physician did not know existed.
This is precisely where the next phase of oncology has to focus
Research breakthroughs are redefining what is possible, but too many patients are still getting lost in a system not built for the realities of modern cancer care. AI powered trial matching, decentralized and outpatient delivery of advanced therapies like CAR T, and platforms built specifically to connect patients with expanded access and compassionate use programs are not side projects. They are the infrastructure that decides whether innovation reaches the people it was built for.
The molecules are getting better every year. Whether patients can reach them is still, largely, a question of navigation, not biology.
At Right2Hope, we see this gap every day. These access gaps do not end at diagnosis or standard treatment. They continue when patients need to navigate clinical trials and investigational treatment options. It is a shortage of patients and physicians knowing that beyond the clinical trial they didn't qualify for, there is often another door: an Expanded Access or Compassionate Use pathway built for exactly this moment.
Closing that gap, one patient, one question, one connection at a time, is the work.